CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma
Cambridge, UK, December 10th, 2024 – CellCentric, a clinical-stage biotechnology company, today announces new data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Emma Searle, Consultant Hematologist at The Christie NHS Foundation Trust, presented promising results from its Phase I/II trial of inobrodib in combination with pomalidomide and dexamethasone (InoPd) […]
CellCentric to Share Latest Inobrodib Phase II Data; Oral Presentation at ASH 2024
Cambridge, UK, November 6th – CellCentric, a clinical stage biotechnology company, today announces that it will deliver an oral presentation on its groundbreaking, oral drug, inobrodib, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The presentation, set for Monday, December 9th, 2024, will be delivered by Dr. Emma Searle, Consultant Hematologist […]
CellCentric Secures $35 Million Investment from RA Capital Management
Cambridge, UK, July 24th, 2024 – CellCentric, a clinical stage biotechnology company, today announces that it has secured a $35 million investment from RA Capital Management. The funding will support the continued development of CellCentric’s oral drug inobrodib, a first-in-class p300/CBP inhibitor, to treat multiple myeloma. Alongside the conversion of a loan note from Pfizer made last […]
CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials
Cambridge, UK, 11th December 2023: CellCentric has announced new clinical data for its oral drug inobrodib at the American Society for Hematology annual meeting (ASH) in San Diego. The data shows over 70% responses (>=MR by IMWG criteria) in last line multiple myeloma patients treated with inobrodib in combination with pom + dex. The results […]
Inobrodib’s novel mechanism: new data published in Cancer Cell
Cambridge, UK, November 2023: CellCentric, a UK-based biotechnology company, today announced the publication of a cornerstone paper in Cancer Cell. The work builds on pre-clinical and clinical collaborations, notably with Professor Tim Somervaille of the Cancer Research UK Manchester Institute. The paper, titled, Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies, reports on […]
CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm
Cambridge, UK, 11h September 2023: CellCentric, a UK-based biotechnology company, today announces it has received a further $3 million investment from BrightEdge LLC, the impact investment and innovation arm of the American Cancer Society (ACS). This funding follows an initial strategic investment in January 2022. The investment will help finance further development of inobrodib, CellCentric’s […]
CellCentric announces $25m strategic investment from Pfizer
Cambridge, UK, July 11, 2023: CellCentric, an innovative UK-based biotechnology company, today announces a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing […]
CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma
Cambridge, UK, June 29th, 2023: CellCentric, a UK-based biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib (CCS1477) in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with […]
CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma
CAMBRIDGE, UK, June 13th, 2023: CellCentric today announces that the US Food and Drug Administration (FDA) has granted its novel cancer drug inobrodib Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma. The FDA’s Fast Track designation is designed to aid the development of new treatments, expediting the review of […]
CellCentric presents early haem clinical data at ASH
Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Cambridge, UK, December 11th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces clinical data for the first time at the 64th American Society of Haematology (ASH) Annual Meeting, New […]